AI Terminal
Oxford Biomedica PLC
Earnings Release • Aug 16, 2022
5190_rns_2022-08-16_8a827931-ad20-4875-a474-6e3359a820f4.html
Earnings Release
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 1472W
Oxford Biomedica PLC
16 August 2022
Oxford Biomedica notes Homology Medicines' quarterly report and confirms financials for Oxford Biomedica Solutions LLC are in line with expectations
Oxford, UK - 16 August 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a leading gene and cell therapy group, notes the release of Homology Medicines' ("Homology") quarterly report for the three months ended 30 June 2022. Financial information on Oxford Biomedica Solutions LLC ("Oxford Biomedica Solutions") contained within Homology's 10-Q is in line with Company expectations. To view Homology's announcement see: Form 10-Q.
Oxford Biomedica Solutions, 20% owned by Homology, is a US-based full scope, AAV manufacturing and innovation business offering a unique 'Plug & Play' platform and fully integrated end-to-end capabilities, including from vector design and process development through to clinical trials.
Oxford Biomedica Solutions has a robust business pipeline and maintains its financial guidance. The Company is committed and confident about securing two new Adeno-Associated Virus (AAV) customer partnerships by the end of calendar year 2022.
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: [email protected]
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Matthew Neal / Matthew Cole
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.
Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, which the Group leverages to develop product candidates in-house, before seeking partners to take the products into clinical trials.
Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica Solutions, a new US based subsidiary AAV manufacturing and innovation business, based near Boston, US.
Oxford Biomedica employs more than 940 people. Further information is available at www.oxb.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCUNOVRUKUWARR